For help on how to get the results you want, see our search tips.
36 results
Medicine
Withdrawn applications Remove Withdrawn applications filter
Summaries of opinion Remove Summaries of opinion filter
Referrals Remove Referrals filter
-
List item
Referral: Picato
ingenol mebutate, associated names: Picato, Article 20 procedures
Status: European Commission final decision, opinion/position date: 30/04/2020, EC decision date: 06/07/2020, Last updated: 16/11/2020 -
List item
Referral: Yondelis
trabectedin, associated names: Yondelis, Article 20 procedures
Status: European Commission final decision, opinion/position date: 24/07/2020, EC decision date: 24/09/2020, Last updated: 09/10/2020 -
List item
Referral: Xeljanz
tofacitinib, associated names: Xeljanz, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 31/01/2020, Last updated: 06/03/2020 -
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020 -
List item
Referral: Lartruvo
olaratumab, associated names: Lartruvo, Article 20 procedures
Status: European Commission final decision, opinion/position date: 31/01/2019, EC decision date: 19/07/2019, Last updated: 22/08/2019 -
List item
Referral: Xofigo
radium Ra223 dichloride, associated names: Xofigo, Article 20 procedures
Status: European Commission final decision, opinion/position date: 26/07/2018, EC decision date: 28/09/2018, Last updated: 11/10/2018 -
List item
Referral: Esmya
ulipristal acetate, associated names: Esmya, Article 20 procedures
Status: European Commission final decision, opinion/position date: 31/05/2018, EC decision date: 26/07/2018, Last updated: 08/08/2018 -
List item
Referral: Zinbryta
daclizumab, associated names: Zinbryta, Article 20 procedures
Status: European Commission final decision, EC decision date: 27/03/2018, Last updated: 11/07/2018 -
List item
Referral: Maci
matrix-applied characterised autologous cultured chondrocytes, associated names: Maci, Article 20 procedures
Status: European Commission final decision, opinion/position date: 25/09/2014, EC decision date: 19/11/2014, Last updated: 05/07/2018 -
List item
Referral: Zinbryta
daclizumab, associated names: Zinbryta, Article 20 procedures
Status: European Commission final decision, opinion/position date: 09/11/2017, EC decision date: 08/01/2018, Last updated: 12/01/2018 -
List item
Referral: SGLT2 inhibitors (previously canagliflozin)
canagliflozin, empagliflozin, dapagliflozin, canagliflozin / metformin, empagliflozin / metformin, dapagliflozin / metformin, associated names: Xigduo, Ebymect, Edistride, Synjardy, Forxiga, Jardiance, Vokanamet, Invokana, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/02/2017, EC decision date: 04/05/2017, Last updated: 08/05/2017 -
List item
Referral: Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)
daclatasvir / dasabuvir / sofosbuvir / ledipasvir / simeprevir / ombitasvir/paritaprevir / ritonavir, associated names: Sovaldi, Olysio, Viekirax, Harvoni, Exviera, Daklinza, Article 20 procedures
Status: European Commission final decision, opinion/position date: 15/12/2016, EC decision date: 23/02/2017, Last updated: 09/03/2017 -
List item
Referral: Zydelig
idelalisib, associated names: Zydelig, Article 20 procedures
Status: European Commission final decision, opinion/position date: 21/07/2016, EC decision date: 15/09/2016, Last updated: 03/10/2016 -
List item
Referral: Closamectin Pour-on Solution and associated names
Ivermectin, closantel, Article 78
Status: European Commission final decision, opinion/position date: 08/10/2015, EC decision date: 22/03/2016, Last updated: 31/05/2016 -
List item
Referral: SGLT2 inhibitors
canagliflozin, dapagliflozin,empagliflozin, associated names: Edistride, Ebymect, Xigduo, Vokanamet, Synjardy, Jardiance, Invokana, Forxiga, Article 20 procedures
Status: European Commission final decision, opinion/position date: 25/02/2016, EC decision date: 28/04/2016, Last updated: 18/05/2016 -
List item
Referral: Tysabri
natalizumab, associated names: Tysabri, Article 20 procedures
Status: European Commission final decision, opinion/position date: 25/02/2016, EC decision date: 25/04/2016, Last updated: 12/05/2016 -
List item
Referral: Human papillomavirus vaccines - Cervarix, Gardasil, Gardasil 9, Silgard
Cervarix : Bivalent HPV vaccine (types 16, 18) -Gardasil : quadrivalent HPV vaccine (types 6, 11, 16, 18)Gardasil 9 : 9-valent HPV vaccine (types 6, 11, 16, 18, 31, 33, 45, 52 and 58)Silgard : quadrivalent HPV vaccine (types 6, 11, 16, 18), associated names: Cervarix, Gardasil, Gardasil 9, Silgard, Article 20 procedures
Status: European Commission final decision, opinion/position date: 19/11/2015, EC decision date: 12/01/2016, Last updated: 20/01/2016 -
List item
Referral: Inductos
dibotermin alfa, associated names: Inductos, Article 20 procedures
Status: European Commission final decision, opinion/position date: 22/10/2015, EC decision date: 20/11/2015, Last updated: 07/12/2015 -
List item
Referral: Iclusig
ponatinib, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/10/2014, EC decision date: 15/01/2015, Last updated: 02/03/2015 -
List item
Referral: Corlentor and Procoralan
ivabradine, associated names: Corlentor and Procoralan, Article 20 procedures
Status: European Commission final decision, opinion/position date: 20/11/2014, EC decision date: 15/01/2015, Last updated: 16/02/2015 -
List item
Referral: Protelos and Osseor
strontium ranelate, Article 20 procedures
Status: European Commission final decision, opinion/position date: 20/02/2014, EC decision date: 15/04/2014, Last updated: 18/09/2014 -
List item
Referral: Bayovac IBR Marker Vivum
bovine Herpes Virus type 1 (BHV-1), strain Difivac (IBR-Marker Virus, gE-negative), modified live (attenuated) virus, associated names: Rhinobovin, Marker lebend, Rhinobovin Marker live, RhinobovinMarker Viva, Rhinobovin Marker Attenuato, Rhinobovin Marker Viva Marcada, Article 78
Status: European Commission final decision, opinion/position date: 21/01/2000, EC decision date: 10/07/2000, Last updated: 05/08/2014 -
List item
Referral: Crestor and associated names
rosuvastatin, Article 29 paediatrics
Status: European Commission final decision, opinion/position date: 30/06/2014, Last updated: 01/08/2014 -
List item
Referral: Kogenate Bayer and Helixate NexGen
octocog alfa, Article 20 procedures
Status: European Commission final decision, opinion/position date: 19/12/2013, EC decision date: 20/02/2014, Last updated: 09/04/2014 -
List item
Referral: Tredaptive, Pelzont and Trevaclyn
laropiprant / nicotinic acid, Article 20 procedures
Status: European Commission final decision, EC decision date: 22/03/2013, Last updated: 17/05/2013